Abstract
Solriamfetol (Sunosi™) is an orally active, selective dopamine and norepinephrine reuptake inhibitor that was recently approved in the USA as a treatment for excessive daytime sleepiness (hypersomnia) associated with narcolepsy and obstructive sleep apnoea (OSA). Norepinephrine and dopamine influence various physiologic functions, including sleep-wake regulation, and excessive sleepiness has been linked with dysregulation of dopaminergic and norepinephrine systems. This article summarizes the milestones in the development of solriamfetol leading to this first approval as a treatment for excessive daytime sleepiness associated with narcolepsy and OSA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jazz Pharmaceuticals. Jazz Pharmaceuticals receives new PDUFA goal date for solriamfetol for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea [media release]. 21 Dec 2018. http://www.jazzpharmaceuticals.com.
Szabo ST, Thorpy MJ, Mayer G, et al. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. Sleep Med Rev. 2019;43:23–36.
Jazz Pharmaceuticals. SUNOSI (solriamfetol) tablets: US prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf. Accessed 01 Apr 2019.
Jazz Pharmaceuticals. Jazz Pharmaceuticals submits marketing authorization application to European Medicines Agency for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea [media release]. 09 Nov 2018. http://www.jazzpharmaceuticals.com.
SK biopharmaceuticals. SK biopharmaceuticals enters into a collaboration agreement to study Lou Gehrig’s Disease [media release]. 19 Sept 2011. http://www.skbp.com.
Addrenex Pharmaceuticals. Addrenex Pharmaceuticals expands product pipeline by licensing new drug to treat narcolepsy [media release]. 13 May 2009. http://w.addrenex.com.
Jazz Pharmaceuticals. Jazz Pharmaceuticals announces acquisition from Aerial Biopharma of rights to a late stage investigational compound for excessive daytime sleepiness [media release]. 13 Jan 2014. http://www.jazzpharmaceuticals.com.
Jazz Pharmaceuticals. Jazz Pharmaceuticals announces full year and fourth quarter 2013 financial results [media release]. 25 Feb 2014. http://www.jazzpharmaceuticals.com.
Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2018;366(2):367–76.
Zomorodi K, Kassir N, Kheibarshekan L. Population pharmacokinetic analysis of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor [abstract no. T-038]. J Pharmacokinet Pharmacodyn. 2018;45(Suppl. 1):S63.
Zomorodi K, Kankam M, Lu Y. A phase I, randomized, crossover, open-label study of the pharmacokinetics of solriamfetol (JZP-110) in healthy adult subjects with and without food. Clin Ther. 2019;41(2):196–204.
Zomorodi K, Chen D, Lee L, et al. Single-dose pharmacokinetics and safety of solriamfetol in participants with normal or impaired renal function and with end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2019;1–10.
Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–70.
Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379–87.
Bogan RK, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102–8.
Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med. 2018. https://doi.org/10.1164/rccm.201806-1100OC.
Strollo PJ Jr, Hedner J, Collop N, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. Chest. 2019;155(2):364–74.
Shapiro C, Schwab R, Pepin JL, et al. A long-term safety and maintenance of efficacy study of solriamfetol (JZP-110) for the treatment of excessive sleepiness associated with narcolepsy or obstructive sleep apnea [abstract no. M309]. Ann Neurol. 2018;84(Suppl. 22):S232–3.
Jazz Pharmaceuticals. Jazz Pharmaceuticals announces U.S. FDA approval of Sunosi™ (solriamfetol) for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea [media release]. 20 Mar 2019. http://www.jazzpharmaceuticals.com.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Markham, A. Solriamfetol: First Global Approval. Drugs 79, 785–790 (2019). https://doi.org/10.1007/s40265-019-01123-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-019-01123-y